DDW 2024: Simple Endoscopic Score for Crohn’s Disease (SES-CD) ≥ 7 Predicts Disease Progression in Patients with Mild CD
Classically, Crohn's disease has been known as a progressive condition, with most patients developing intestinal complications requiring surgery within 20 years of diagnosis. However, a subset of patients experiences a milder disease course, avoiding complications and advanced therapy. Identifying these individuals with mild Crohn’s disease may impact treatment decisions, preventing unnecessary immunosuppressive treatments. Challenges in managing mild Crohn’s disease stem from limited data, mostly derived from clinical trials focusing on moderate to severe cases. This leads to a lack of clear management recommendations due to the absence of formally validated consensus definitions for mild Crohn’s disease. The speaker presented a study aimed at examining the association of SES-CD with long-term outcomes in mild Crohn’s disease patients and validating existing SES-CD cutoffs indicating a lower risk of disease progression. The study, a multi-center retrospective analysis, included cohorts from two IBD centers, Mass General Hospital and Mount Sinai Hospital. Adult patients with Crohn's disease undergoing colonoscopy were included if they had no prior Crohn's disease-related surgery and were not on immunomodulator or biological therapy at the time of assessment. Endoscopic severity was scored using the SES-CD system, with additional variables obtained through electronic medical record review. The primary outcome was disease progression at two and five years post-endoscopic assessment, defined by the initiation of therapy or development of complications. Univariate and multivariate Cox proportional hazard models were used to identify predictors of disease progression, with total SES-CD as the primary variable of interest. Subgroup analysis was conducted based on prior therapy use.
The final study cohort consisted of 146 patients. Most patients had established Crohn's disease, with a mean disease duration of approximately 17 years. The majority exhibited ileocolonic or colonic involvement, and while most had a non-complicated phenotype, some had complicated phenotypes and perianal disease. While 45% had a remote history of immunomodulator or biologic use, they were not using these medications at the time of assessment. The majority had an SES-CD score between 0 and 6, with a mean SES-CD of 3.8. At two years, the composite primary outcome occurred in 27% of patients, increasing to 39% at five years, leaving 60% with mild disease at five years. Disease progression rates were notably higher in those with an SES-CD greater than 7 compared to those with an SES-CD of 0, 1 to 3, or 4 to 6. Restricting the analysis to patients who had never received immunomodulators or biologics, an SES-CD greater than 7 remained significantly associated with disease progression at two and five years, with hazard ratios of 2.5 and 2.8 respectively. Among patients with an SES-CD greater than 7, total SES-CD was more predictive of disease progression in those with ileal and ileocolonic disease compared to those with isolated colonic disease. In multivariable analysis, total SES-CD was independently associated with disease progression at two and five years, along with prior immunosuppressant use and disease duration.
The study had certain limitations, including its retrospective nature, which introduced inherent biases and limitations associated with data collection. Additionally, the heterogeneous nature of the study population was acknowledged, particularly the small proportion of patients with a remote exposure to biologics or immunosuppressive therapies, who also had complicated phenotypes, not aligning with the typical definition of mild Crohn’s disease. Lastly, the use of a referral cohort likely represented a more complex patient population overall, potentially underestimating the prevalence of mild Crohn’s disease. In conclusion, in patients with longstanding Crohn's disease and mild endoscopic activity without receiving any active immunosuppression, the likelihood of disease progression was found to be low. The study supported using an SES-CD cutoff of 1 to 6 to define mild Crohn's disease. Implementing a standardized definition of mild Crohn's disease in clinical practice and clinical trials was suggested to improve Crohn's disease management and aid in the development of new therapeutic strategies for patients with milder forms of the disease. In terms of future directions, the researchers were working on and intended to continue working on larger population-based studies of the prevalence and outcomes of mild Crohn’s disease. They also planned to explore the use of cross-sectional imaging to define risk factors for disease progression, prospectively validate endoscopy and combination biomarkers, investigate translational and multi-omic biomarkers to identify patients at low risk of progression, and conduct trials of therapies and therapeutic strategies.
The audience questioned whether the outcomes were influenced by the colonoscopy procedure itself, potentially biasing results due to treatment initiation prompted by severe disease findings. The speaker explained the inclusion of treatment initiation aimed to capture disease progression complications comprehensively within the study's short duration. Another query addressed the SES-CD measure's ability to capture disease activity across a spectrum. The speaker acknowledged this concern but noted their study did not address it. They suggested modified scoring systems as a potential solution for future research. A participant expressed scepticism about categorizing cases as mild Crohn's disease, citing perianal disease and prior biologic exposure. The speaker explained the limited sample size of treatment-naïve patients hindered further analysis, recommending larger studies for a better understanding. The final question sought clarification on colonoscopy indications. The speaker confirmed they were staging procedures, conducted routinely for staging purposes, rather than symptom-based.
Digestive Disease Week (DDW) 2024, May 18-21, 2024, Washington, D.C.



